首页> 美国卫生研究院文献>other >MNGI-14. LOSS OF HISTONE H3K27me3 IDENTIFIES A SUBSET OF MENINGIOMAS WITH INCREASED RISK OF RECURRENCE
【2h】

MNGI-14. LOSS OF HISTONE H3K27me3 IDENTIFIES A SUBSET OF MENINGIOMAS WITH INCREASED RISK OF RECURRENCE

机译:MNGI-14。组蛋白H3K27me3的丢失可识别出脑膜瘤的一个子集该子集的复发风险增加

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Epigenetic patterns on the level of DNA methylation have already shown to separate clinically relevant subgroups of meningiomas. Based on a reference set (Sahm et al., Lancet Oncol 2017), an epigenetic meningioma classifier employing DNA methylation patterns is made available through molecularneurpathology.org. We now set out to identify prognostic implications of epigenetic modification on the proteome level, particularly modifications of histones. First focus was on H3K27 trimethylation (H3K27me3). H3K27me3 was assessed by immunohistochemistry on 232 meningiomas. In 194 cases, trimethylation was detected in tumor cells. In 25 cases, staining was limited to vessels while all tumor cells were negative. Finally, 13 cases yielded equivocal staining patterns. Reduced abundance of H3K27me3 in cases with staining limited to vessels was confirmed by mass spectrometry on a subset of cases. Lack of staining for H3K27me3 in all tumor cells was significantly associated with more rapid progression (p=0.009). In line, H3K27me3 negative cases were associated with a DNA methylation pattern of the more aggressive types among the recently introduced DNA methylation groups. Also, NF2 and SUFU mutations were enriched among cases with lack of H3K27me3 in tumor cells (p<0.0001 and p=0.029, respectively). H3K27me3 staining pattern added significant prognostic insight in WHO grade II cases and in the compound subset of WHO grade I and II cases (p=0.04 and p=0.007, respectively). However, it did not further stratify within WHO grade III cases. Collectively, this data indicate that epigenetic modifications beyond DNA methylation are involved in the aggressiveness of meningioma. It also suggests that H3K27me3 immunohistochemistry might be a useful adjunct in meningioma diagnostics, particularly for cases with WHO grade II histology or at the borderline between WHO grade I and II. Ongoing studies evaluate the role of histone marks other than H3K27me3 and consequences on the proteomic composition of meningioma cells by high-throughput mass spectrometry.
机译:DNA甲基化水平的表观遗传模式已显示可将临床相关的脑膜瘤亚组分开。基于参考集(Sahm等人,Lancet Oncol 2017),可通过Molecularneurpathology.org获得采用DNA甲基化模式的表观遗传性脑膜瘤分类器。现在我们着手确定表观遗传修饰在蛋白质组水平上的预后意义,尤其是组蛋白的修饰。首先关注的是H3K27三甲基化(H3K27me3)。 H3K27me3通过免疫组化评估了232例脑膜瘤。在194例中,在肿瘤细胞中检测到三甲基化。在25例中,染色仅限于血管,而所有肿瘤细胞均为阴性。最后,13例产生了模棱两可的染色模式。在一部分病例中通过质谱法确认了仅限于血管染色的病例中H3K27me3的丰度降低。所有肿瘤细胞中H3K27me3缺乏染色与更快速的进展显着相关(p = 0.009)。与之相符的是,H3K27me3阴性病例与最近引入的DNA甲基化基团中更具攻击性的DNA甲基化模式有关。此外,在肿瘤细胞中缺乏H3K27me3的病例中,NF2和SUFU突变丰富(分别为p <0.0001和p = 0.029)。 H3K27me3染色模式在WHO II级患者以及WHO I和II级患者的复合亚组中分别增加了重要的预后见解(分别为p = 0.04和p = 0.007)。但是,它没有在WHO的III级病例中进一步分层。总体而言,该数据表明,超出DNA甲基化的表观遗传修饰与脑膜瘤的侵袭性有关。这也表明,H3K27me3免疫组化在脑膜瘤诊断中可能是有用的辅助手段,特别是对于具有WHO II级组织学或处于WHO I和II级边界的病例。正在进行的研究通过高通量质谱法评估了H3K27me3以外的组蛋白标记的作用以及对脑膜瘤细胞蛋白质组学组成的影响。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号